~~<i id='350B398D5E'><strike id='350B398D5E'><tt id='350B398D5E'><pre id='350B398D5E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

focus

author：knowledge 2025-09-03 03:27:21 - browse：8

LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for $1 billion upfront, the latest in a string of pharma acquisitions that are bolstering hopes for the industry’s year ahead.

The deal includes up to another $400 million in payments if certain milestones are met.

Aiolos was launched just last year, based in both San Francisco and London. The company, which announced a $245 million Series A round in October, has been readying a Phase 2 trial of its candidate AIO-001 in adult asthma.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： More tobacco lobbyists active in statehouses

hotspot

explore

leisure time

focus

Wikipedia

hotspot

AlexHogan/STATWASHINGTON—Healthcarecostsaregettingsohighthatpricesareliterallyrunningoffofthepage.Me

WSS

An outrageous hospital charge: I paid $710 for an hour of babysitting

H5N1 bird flu virus started spreading in cows in Texas in December

McConnell had minor fall 2 weeks ago, uses wheelchair periodically to get around: Sources

Diversity in clinical trials starts with building trust, experts say

Will biotech layoffs continue through 2023?

H5N1 bird flu found in pasteurized milk: what we know

knowledge

focus

hotspot

Medicare details structure of new drug price negotiation program

As the dark side of IVF slowly comes into focus, even more transparency is needed

BioMarin wins approval for gene therapy to treat hemophilia A

Hospitals, health systems can help patients avoid medical debt

ChatGPT in medicine: STAT answers readers' burning questions

UnitedHealth financials solid despite Change Healthcare cyberattack

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Cell therapy fails to slow type 1 diabetes, but safety is established

Duchenne breakthrough therapy leaves behind pioneering families

Melinda French Gates resigns from Gates Foundation

explore

Public health communication lessons from Covid

Key Senate committee drafts bipartisan bill to stem drug shortages

'The boss' wants server deleted: New allegations emerge in Trump indictment

Bird flu outbreak in cows is latest avian flu curveball

Element Biosciences CEO lays out genome sequencing strategy

Why does health care cost so much? A reading guide

leisure time

focus

Wikipedia

hotspot